

1 **Thomas Jefferson University**
2 **Informed Consent Document for Human Subjects Research – OHR-8**
3 **Version Date – FOR OHR USE: 9/1/16**
4

5 **Department:** Otolaryngology

6
7 **Principal Investigator:** Mindy Rabinowitz, MD, Otolaryngology **Telephone:** 215 955 6760
8

9 **Co-Investigator(s):** Gregory Epps MD, Marc Rosen, MD, Gurston Nyquist, MD, Jason
10 Jerusik PharmD **Telephone:** 215 955 6760
11

12 **Medical Study Title:** Treatment of Post-Operative Sinonasal Polyposis with Topical Furosemide
13

14 **Lay Study Title:** A research study to evaluate the effect of a nasal spray containing furosemide
15 (Lasix) on nasal polyps following sinus surgery.
16

17 **What Is Informed Consent?**
18

19 You are being asked to take part in a medical research study. As required by federal regulations,
20 this research study has been reviewed and approved by an Institutional Review Board (IRB), a
21 University committee that reviews, approves and monitors research involving humans. Before a
22 knowledgeable decision about whether to participate in a research study can be made, the
23 possible risks and benefits related to the study should be understood. This process of learning and
24 thinking about a study before deciding to participate is known as *informed consent* and includes:

- 25 • Receiving detailed information about this research study;
- 26 • Being asked to read, sign and date this consent form once the nature of the study is
27 understood and a decision is made to participate. If there is anything about the study you
28 don't understand or if there are questions, you should ask for explanations before signing
29 this form;
- 30 • Being given a copy of the signed and dated consent form to keep.
31

32 A patient who joins a research study has a relationship with the study doctor that is different than
33 the relationship with a treating or personal doctor. A treating doctor treats a specific health
34 condition with the goal of improving that condition. A study doctor treats all subjects according
35 to a research plan to obtain information about the experimental drug, device or procedure being
36 studied and with the understanding that there may or may not be benefit from being in the study.
37 The study doctor and study staff can provide more information about research as opposed to
38 treatment.
39

40 The type of study you are being asked to join is known as a pilot study.
41

42 A pilot study is one that is done to collect information to determine whether a larger,
43 scientifically rigorous study should or should not be undertaken.
44
45

Thomas Jefferson University IRB/OHR
Approval Date: 11/20/20
Expiration Date: 3/10/21
Annual review due 6 wks before expiration

46 **What is the purpose of this study?**

47 This study aims to evaluate if topical furosemide may reduce or prevent the recurrence of
48 sinonasal polyposis following sinus surgery.

49

50 **How many individuals will participate in the study and how long will the study last?**

51 **100** patients will participate nationally. We hope to enroll **all** patients at Jefferson. Each
52 participant will be in the study for about 6 **months**

53

54 **What will happen during the study?**

55 You will be randomized into either a treatment group or a placebo group to receive a 6 week
56 course of twice a day nasal spray after undergoing surgery for nasal polyps. You will be
57 randomly put into either group like flipping a coin. If you are put into the treatment group you
58 will receive furosemide in a nasal spray. If you are put into the placebo group, you will receive
59 saline in a nasal spray. Neither you nor your doctor will be aware of what group you are in. You
60 will receive an unmarked bottle of nasal spray. You will be given a subject diary to fill out for
61 any days you miss a dose. Post-operative visits will be scheduled at 1 week, 3 week, 2 months, 4
62 months and 6 months where the effect of treatment will be assessed through a physical exam and
63 any symptoms you may be having. These results will be compared to pre-operative values and
64 between groups to see if a difference exists.

65

66 **What are the side effects and other risks or discomforts involved?**

67 Tell the study doctor or research team as soon as possible if any of the side effects, risks or
68 discomforts listed below occur or if you think a side effect that is not listed may be happening.

69

70 If your condition worsens, if side effects become very severe, or if it turns out that being in this
71 study is not in your best interest, you will be taken out of the study.

72

73 If questions come up about side effects, ask the study doctor or staff at any time during or after
74 the study.

75

76 Common, some may be serious, could happen in 20% or more of subjects

- 77 • Nasal irritation or bleeding.

78

79 Occasional, some may be serious, could happen in 3-20% of subjects

- 80 • nausea or vomiting
- 81 • diarrhea
- 82 • constipation
- 83 • stomach cramping
- 84 • feeling like you or the room is spinning (vertigo)
- 85 • dizziness
- 86 • headache
- 87 • blurred vision
- 88 • itching or rash

89

90 Rare and serious, possible in up to 3% of subjects

91 • Excessive loss of water and electrolytes. Symptoms can include:

- 92 ○ dry mouth
- 93 ○ feeling of thirst
- 94 ○ weakness
- 95 ○ drowsiness
- 96 ○ restlessness
- 97 ○ muscle pains or cramps
- 98 ○ urinating less
- 99 ○ fast or abnormal heartbeat
- 100 ○ severe nausea or vomiting

101 • Hearing loss

102
103 If the study doctor decides it is necessary, at study visits or at other times, blood tests will be
104 done to check the function of your heart, lungs, liver, kidneys, and bone marrow (where blood
105 cells are produced). Abnormal tests will be assessed by the study doctor who will determine if
106 further testing is necessary. The study doctor will discuss test results with you.

107
108 Furosemide should not be taken with a group of medicines called aminoglycosides. At any point
109 in the study, if you need to begin taking an aminoglycoside you should tell the study team and
110 you will be taken out of the study. You will be provided with a list of the names of the
111 aminoglycosides.

112
113 **What are the risks to fetuses, infants and pregnant women?**
114 Pregnant women or women who are breast feeding will not be enrolled in this study. To be in this
115 study you and your partner must practice adequate birth control measures. The study doctor will
116 discuss acceptable methods of birth control with you. If you are a woman of childbearing
117 potential, you will have a pregnancy test before making a decision about being in this study. The
118 results of this pregnancy test will be made available to you.

119
120 If you become pregnant during the course of this study, you should notify the study doctor as
121 soon as possible.

122
123 If you are a man participating in this study, you also should practice adequate birth control
124 because of potential adverse effects on sperm. If your partner becomes pregnant during the
125 course of the study, the sponsor may want to follow her through the pregnancy and receive
126 information on the pregnancy outcome. She will be asked to sign a separate consent form or a
127 release of medical information form.

128
129 If you are a person in a same sex relationship, it is not necessary for you to practice birth control.
130 However, if you are female, you will still have to have pregnancy tests according to the study
131 protocol.

132

133 **Are there benefits from being in this study?**

134 There may be no benefit from being in this research, but we hope that what we learn may be
135 helpful to future patients or society in general. Possible benefits from being in the study may
136 include: prevention or reduced recurrence of nasal polyps.

137
138 **Are there alternatives to being in the study?**
139 Participation in this study is entirely voluntary. There may be other alternatives that could be
140 considered. These alternatives would include: the current standard of treatment involving
141 perioperative medications and surgery without the study drug, topical furosemide.

142
143 The study doctor will provide information about the study and any alternative treatments
144 available.

145
146 **How will privacy and confidentiality (identity) be protected?**

147 Federal regulations require that certain information about individuals be kept confidential. This
148 information is called “protected health information” (PHI). PHI includes information that
149 identifies an individual personally such as name, address and social security number, or any
150 medical or mental health record, or test result, that may have this sort of information on it. The
151 laws state that people may see and review their medical records at any time. However, in a
152 research study, people may not see the study results or other data about the study until after the
153 research is completed unless the study doctor decides otherwise.

154
155 The following individuals or entities may have access to your PHI and by law must protect it.
156 These include investigators listed on this consent form and other personnel of Thomas Jefferson
157 University, Jefferson University Physicians, and Thomas Jefferson University Hospitals, Inc.
158 involved in this specific study, the University’s Office of Human Research and the Institutional
159 Review Board (IRB), and your health insurance company.

160
161 PHI collected during this study may also be shared with the following entities that, while not
162 obligated by law to protect PHI, will protect it to the best of their ability:

- 163 • With any person or agency required by law.

164
165 The following information will be provided to the entities noted above:

166
167 **Study data for analysis:** Lund Kennedy score, Meltzer endoscopic score, SNOT-22 score

168
169 **Demographic data:** age, sex, past medical history, past surgical history, allergies, medications

170
171 If you develop an illness or injury during the course of participation in this study, other PHI
172 about treating and following the condition may be generated and disclosed as it relates to this
173 study.

174
175 PHI collected as part of this research may be used/disclosed until the end of the research study.

176

177 You may quit the study and revoke permission to use and share PHI at any time by contacting the
178 principal investigator, in writing, at:

179
180 Dr. Mindy R. Rabinowitz, MD
181 Assistant Professor
182 Rhinology and Endoscopic Skull Base Surgery
183 Thomas Jefferson University
184 Department of Otolaryngology - Head & Neck Surgery
185 925 Chestnut Street, 6th floor
186 Philadelphia, PA 19107

187
188 Further collection of PHI will be stopped on those who quit the study, but PHI that has already
189 been collected may still be used.

190
191 The results of clinical tests and procedures performed as part of this research may be included in
192 your medical records. The information from this study may be published in scientific journals or
193 presented at scientific meetings but no one will be personally identified in these publications and
194 presentations.

195
196 A description of this clinical trial will be available on <http://www.ClinicalTrials.gov>, as required
197 by U.S. Law. This Web site will not include information that can identify you. At most, the Web
198 site will include a summary of the results. You can search this Web site at any time.

199
200 **What happens in case of injury as a result of being in this study?**
201 In the event of a research-related injury, necessary and available medical care (including
202 hospitalization) will be provided. A research-related injury is a physical injury or illness that is
203 directly caused by any procedure or treatment used in this study that is different from the
204 treatment you would receive if not participating in a research study. If physical injury occurs due
205 to any drug/substance or procedure properly given under the plan for this study, medical
206 expenses for treating the injury will be billed to your insurance carrier. Costs not covered by your
207 insurance, a government program or by another 3rd party may be paid for by the sponsor of this
208 study. There is no plan to provide compensation for loss of wages, lost time from work, personal
209 discomfort, or for injuries or problems related to your underlying medical condition(s).

210
211 If you have questions about the sponsor's agreement regarding payment for a research-related
212 injury please discuss with the study doctor.

213
214 If a bill related to a research-related injury is received that seems wrong, please discuss it with
215 the study doctor or research coordinator.

216
217 **Is there payment for being in this study?**
218 There is not payment for participating in this study.

219
220 **Are there costs related to being in this study?**
221 There are no costs related to being in this study.

222
223 ***Research Procedures***
224 There are no charges to you or your insurance carrier for study visits or tests that are part of this
225 research. The investigational agent will be provided by the sponsor free of charge.
226

227 ***Standard Testing Procedures***
228 Standard of care procedures and doctor visits will be billed to your health insurance carrier.
229 These are charges that would be billed to insurance whether in a research study or not. It is
230 possible that insurance coverage may be denied. If that happens you may be responsible for some
231 or all of these charges. The study doctor will explain which procedures, tests and doctor visits are
232 considered standard of care.

233
234 If a bill is received that you think is wrong, please discuss it with the study doctor or research
235 coordinator.
236

237 **What if the research results in new findings?**
238 Anything learned during the study, beneficial or not, that may affect your health or willingness to
239 continue in the study, will be explained.
240

241 **Can I be removed from the study or quit the study?**
242 Your decision to participate in this research study is entirely voluntary. You have been told what
243 being in this study will involve, including the possible risks and benefits.
244

245 Your participation in this research project may be terminated by the study doctor without your
246 consent/assent for any reason that she feels is appropriate.
247

248 You may refuse to participate in this investigation or withdraw consent and quit this study
249 without penalty and without affecting the ability to receive medical care at Thomas Jefferson
250 University.
251

252 If you withdraw from this study, you may continue treatment with your Jefferson doctor, or you
253 may seek treatment from another doctor of your choice.
254

255 Should you decide to withdraw from the study, please be sure to inform the study doctor.
256 Additional tests or procedures may be needed to ensure your safety. The study doctor will
257 explain why these tests or procedures are necessary.

258
259
260
261
262
263
264
265
266

CONTACT INFORMATION

If you are having a medical emergency, call 911 or go directly to an emergency room. You should let emergency personnel or providers know that you are participating in this study.

Telephone number for questions about your rights as a research participant	The Jefferson Institutional Review Board	215-503-8966
For questions, concerns or complaints about the research, or if you suspect a research-related injury	The Principal Investigator, Dr. Mindy Rabinowitz or any co-investigator listed at the beginning of this form	215 955-6760
If you have difficulty contacting the study staff	Call the Jefferson Office of Human Research	215-503-0203

267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286

If you want more information about the Jefferson Institutional Review Board or Jefferson's Human Research Protection Program, please visit our website at http://www.jefferson.edu/human_research/irb/index.cfm.

Subject Communications

Do you wish to communicate with the study staff by e-mail? YES _____ NO _____

If you checked yes, please print your e-mail address on the line below.

RISKS: Steps are taken to protect your confidentiality when sending information by e-mail. However, e-mail is not always secure. There is always the risk that personal information sent by email could be seen by someone other than you.

YOU SHOULD NEVER USE E-MAIL TO REPORT A SUSPECTED ADVERSE EVENT OR ANY OTHER MEDICAL PROBLEM. THESE SHOULD BE REPORTED BY TELEPHONE.

287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327

Signatures

Patient/Subject: By signing this form, you are agreeing that:

- You were given the opportunity to read this form.
- All of the information in this form was discussed with you by an investigator or other research personnel to your satisfaction.
- All your questions have been answered to your satisfaction.
- You were not pressured and you voluntarily agree to take part in this research.

_____	_____	_____
Your Name	Your Signature	Date

_____	_____	_____
Name of Person Obtaining/ Assisting with Consent	Signature of Person Obtaining/ Assisting with Consent	Date

The physician investigator's signature certifies that s/he personally provided the study participant with a description of the study, study procedures, risks, benefits and alternatives to participation.

_____	_____	_____
Name of Investigator or Co-Investigator	Signature of Investigator or Co-Investigator	Date

_____	_____	_____
Name of Witness	Signature of Witness	Date

(Witness required if the only language the subject speaks and understands is English, but the subject cannot read English, or if the subject is blind or cannot physically sign the consent form.)

Copy of Signed and Dated Consent Form Given to the Patient/Subject

As Per University Counsel - Do Not Sign
This Consent Form After 3/10/21

328 **Teach-Back Questions** – These questions can be asked to help ensure that the patient
329 understands the study.

330

331 Check this box if these questions were reviewed with the patient.

332

333 We have gone over a lot of information. I would like to ask you a few questions to make sure I
334 have done a good job explaining the study to you.

335

336 1. In your own words, please answer these questions about this study:

337

a. Why are we doing this study (what are we trying to learn)?

338

b. What things (including tests and procedures) will you have to do in this study?

339

c. What are some of the risks of being in this study?

340

d. What is the benefit of being in this study?

341

e. How will being in this study be different than usual medical care?

342

f. How long will you be in this study?

343

2. Taking part in this study is voluntary. What does that mean to you?

344

a. If you don't want to be in this study, what are your other choices?

345

b. What will happen if you chose not to be in this study?

346

3. What will we do to make sure your information remains confidential?

347

4. What other questions do you have about this study?